PMID: 3662276Nov 1, 1987Paper

Intravenous verapamil for treatment of multifocal atrial tachycardia with and without calcium pretreatment

Annals of Internal Medicine
D M SalernoC Iber


Verapamil was given to 16 consecutive patients with multifocal atrial tachycardia. Intravenous verapamil was administered at a rate of up to 1 mg/min while heart rate and systolic blood pressure were being monitored. The final 5 patients received 1 g of intravenous calcium gluconate 5 minutes before treatment with verapamil; the first 11 received no calcium. The mean +/- SD heart rate decreased by 21% from 129 to 101 beats/min, a difference of 28, 95% confidence interval (CI), 18 to 38 (p less than 0.0005 by t-test), after a mean of 22 +/- 13 minutes from the start of verapamil administration. The mean verapamil dose was 17 +/- 7 mg (6 to 30 mg). Sinus rhythm was restored in 8 patients. Pretreatment with calcium did not block the effect of verapamil on heart rate (27% decrease with calcium compared with 19% decrease without calcium, a difference of 8%, 95% CI, -7 to 23; p = 0.29) but minimized the decrease in systolic pressure (11% decrease with calcium compared with 27% decrease without calcium, a difference of 16%, 95% CI, 7 to 27; p less than 0.01). Verapamil caused transient asymptomatic hypotension in 1 patient. Arterial blood gases were unchanged by verapamil. Thus, verapamil is safe and effective therapy for multifocal a...Continue Reading


Oct 11, 1991·Journal of the American College of Cardiology·D H WohnsK F Adams
Jan 1, 1989·The Journal of Emergency Medicine·G P Moore, D W Munter
Jan 19, 1995·The New England Journal of Medicine·L I Ganz, P L Friedman
Jul 1, 1995·The American Journal of Emergency Medicine·R B Vukmir
Jul 1, 1992·American Heart Journal·M Kuhn, D L Schriger
Jul 1, 1992·Current Problems in Cardiology·D E Haines, J P DiMarco
May 1, 1994·The Journal of Emergency Medicine·M SchwartzS R Lowenstein
Jan 1, 1992·Annals of Emergency Medicine·S J Jameson, S W Hargarten
Sep 1, 1989·American Heart Journal·D L Scher, E L Arsura
Jul 29, 2018·American Journal of Medical Genetics. Part a·Mark D LevinAngela E Lin
Oct 1, 1989·Postgraduate Medicine·S L Lawhorn, W W Emmot
Jun 14, 2000·The Annals of Pharmacotherapy·L R MoserJ E Tisdale
Jun 14, 1990·The New England Journal of Medicine·J A Kastor
May 1, 1992·Postgraduate Medicine·D M Salerno

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.


Bradyarrhythmias are slow heart rates. Symptoms may include syncope, dizziness, fatigure, shortness of breath, and chest pains. Find the latest research on bradyarrhythmias here.


Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.